Home/Filings/4/0001654954-22-012922
4//SEC Filing

Rich Stuart 4

Accession 0001654954-22-012922

CIK 0000034956other

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 4:32 PM ET

Size

11.0 KB

Accession

0001654954-22-012922

Insider Transaction Report

Form 4
Period: 2022-09-21
Rich Stuart
DirectorChief Medical Officer
Transactions
  • Gift

    Common Stock

    2022-09-21+1,909,5851,909,585 total(indirect: By Trust)
  • Gift

    Common Stock

    2022-09-211,909,585424,347 total
Holdings
  • Stock Option (right to buy)

    Exercise: $1.78Exp: 2031-01-15Common Stock (250,000 underlying)
    250,000
  • Common Stock

    (indirect: By Trust)
    1,909,585
  • Stock Option (right to buy)

    Exercise: $0.62Exp: 2032-06-09Common Stock (100,000 underlying)
    100,000
Footnotes (5)
  • [F1]Represents a gift of Issuer's common stock to the Stuart Rich 2022 Irrevocable Trust. a Spousal Lifetime Access Trust (the "Trust"), for the benefit of Reporting Person's spouse and their children.
  • [F2]The Reporting Person is special asset advisor to the Trust. As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
  • [F3]The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  • [F4]The option becomes exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
  • [F5]The options vest and become exercisable as follows: options with respect to 25,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.

Issuer

TENAX THERAPEUTICS, INC.

CIK 0000034956

Entity typeother

Related Parties

1
  • filerCIK 0001841785

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:32 PM ET
Size
11.0 KB